Patient Profiles in HER2-Positive Breast Cancer : Episode 12
Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC
Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.
EP: 1.HER2+ Breast Cancer: Overview of the Treatment Armamentarium
EP: 2.Selecting and Sequencing Therapy for HER2+ Breast Cancer
EP: 3.Recent Trial Data in HER2+ Metastatic Breast Cancer
EP: 4.Patient Profile 1: Frontline Therapy for HER2+ mBC
EP: 5.Patient Profile 1: Second-Line Therapy for HER2+ mBC
EP: 6.Patient Profile 1: Sequencing Therapies in HER2+ mBC
EP: 7.Patient Profile 2: Patient with Triple-Positive mBC
EP: 8.Patient Profile 2: Second-Line Therapy for Triple-Positive mBC
EP: 9.Patient Profile 2: 3L Therapy for Triple-Positive mBC
EP: 10.Considering Novel Therapy for HER2+ Metastatic Breast Cancer
EP: 11.Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer
Now Viewing
EP: 12.Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC
EP: 13.Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer
EP: 14.Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer
EP: 15.Patient Profile 2: How Should T-DM1 Be Sequenced in HER2+ mBC?
EP: 16.Patient Profile 2: Clinical Utility of the HER2CLIMB Regimen for HER2+ mBC
EP: 17.Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases
EP: 18.Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy
EP: 19.Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer
EP: 20.Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan
EP: 21.Patient Profile 4: Managing AEs in Patients Receiving Treatment for HER2+ BC
EP: 22.Patient Profile 5: Strategies for Managing Elevated Liver Function Tests in Patients on the HER2CLIMB Regimen
EP: 23.Future Directions in the Management of HER2+ Breast Cancer
Related Videos
Related Content
